KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $4.0 billion.

  • Pfizer's Free Cash Flow fell 74.42% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 2619.85%. This contributed to the annual value of $9.8 billion for FY2024, which is 10519.51% up from last year.
  • Pfizer's Free Cash Flow amounted to $4.0 billion in Q3 2025, which was down 74.42% from -$1.2 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Free Cash Flow registered a high of $25.3 billion during Q4 2021, and its lowest value of -$2.4 billion during Q2 2024.
  • Over the past 5 years, Pfizer's median Free Cash Flow value was $4.0 billion (recorded in 2021), while the average stood at $5.2 billion.
  • In the last 5 years, Pfizer's Free Cash Flow tumbled by 12857.91% in 2023 and then skyrocketed by 42876.71% in 2024.
  • Pfizer's Free Cash Flow (Quarter) stood at $25.3 billion in 2021, then fell by 27.03% to $18.5 billion in 2022, then crashed by 77.26% to $4.2 billion in 2023, then fell by 3.93% to $4.0 billion in 2024, then decreased by 0.74% to $4.0 billion in 2025.
  • Its Free Cash Flow was $4.0 billion in Q3 2025, compared to -$1.2 billion in Q2 2025 and $1.8 billion in Q1 2025.